Mictonorm

Propiverine Hydrochloride, the active ingredient in Mictonorm, is an antimuscarinic (muscarinic antagonist) presented as an oral tablet for oral use. It is employed to treat symptoms of overactive bladder, including urgency, frequency, and nocturia, in adult patients.

GNH USA supplies Mictonorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for consistent product availability. GNH USA also offers regulatory support and documentation for importers. Customers benefit from competitive pricing and responsive technical assistance.

Propiverine Hydrochloride acts on the urinary bladder's muscarinic receptors to alleviate overactive bladder symptoms.

Overactive bladder: reduces urgency and frequency of urination. Urge urinary incontinence: decreases episodes of involuntary urine loss. Nocturia: lowers nighttime voiding episodes. Urinary frequency: improves bladder capacity and reduces daytime frequency.

Propiverine Hydrochloride may cause adverse reactions, which are categorized by frequency.

Common Side Effects: - Dry mouth - Constipation - Blurred vision - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Urinary retention - Severe allergic reaction (anaphylaxis) - Tachycardia - Elevated liver enzymes - Angle‑closure glaucoma - Severe skin reactions (Stevens‑Johnson syndrome)

When prescribing Propiverine Hydrochloride, consider the following precautions.

Renal impairment: adjust therapy based on renal function. Hepatic disease: use with caution in patients with liver dysfunction. Elderly patients: monitor for increased anticholinergic effects. Driving and machinery: avoid until individual response is known. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Propiverine Hydrochloride can interact with other medicines; review the following.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase plasma levels of propiverine. - Anticholinergic agents: additive anticholinergic burden. - QT‑prolonging drugs: risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce efficacy. - Diuretics: may exacerbate urinary retention. - Alcohol: may enhance dizziness.